Tag: Cabometyx
Ipsen: RBC welcomes data on Cabometyx
(CercleFinance.com) – RBC reaffirms its ‘performance in line with the sector’ recommendation and its price target of 120 euros on Ipsen, after the presentation of positive phase III data concerning…
Ipsen: encouraging data on Cabometyx expected at ASCO
(CercleFinance.com) – Ipsen announces that encouraging data will be presented on its Cabometyx (cabozantinib), for a variety of cancer types at the annual meeting of the American Society of Clinical…
Ipsen: Favorable opinion from the EMA for Cabometyx
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Ipsen: new for Cabometyx in combination with Opdivo
(Boursier.com) — Ipsen announced the results of analyzes from the Phase III CheckMate -9ER study over a two-year follow-up period (25.4 months minimum; median 32.9 months), which demonstrated sustained benefits…
Ipsen: positive phase 3 results for Cabometyx in kidney cancer – 02/15/2022 at 10:06
(AOF) – Ipsen has announced the results of analyzes from the Phase 3 study which demonstrated sustained benefits in terms of survival and response rates, as well as improved health-related…
Ipsen: Combined with Opdivo, Cabometyx improves survival for kidney cancer patients
PARIS (Agefi-Dow Jones)–The pharmaceutical group Ipsen on Tuesday announced the results of analyzes of the phase 3 CheckMate -9ER study, which demonstrated sustained benefits in terms of survival and response…